Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In vitro and in vivo action of levamisole has been studied in patients with Hodgkin's disease. In vitro levamisole significantly increased the active T cell count of 35 untreated active patients, of those being in complete remission after treatment and of 19 healthy controls; it significantly raised the total T cell count of patients. However, levamisole could not further improve the considerably increased active and total spontaneous rosette formation resulting from in vivo levamisole treatment. Twenty patients with Hodgkin's disease, being in complete remission, were given levamisole for 3 or 6 months, according to 2 different schedules. Levamisole (150 mg) given on 3 consecutive days of every second week for 3 months considerably increased the number of positive skin tests (from 8/60 to 29/60), the numbers of active and total T cells with unchanged absolute lymphocyte count, and decreased the quantity of circulating immune complex. Continuation of treatment for another 3 months resulted in slight, but consistent, decline in all the above parameters; the ratio of active T cells significantly decreased. This decline was even more pronounced if a raised larger dosage of levamisole was administered for 6 months. In the course of the treatment no side-effect or complication was observed. Levamisole is able to improve the weak cellular immune reactivity of patients with Hodgkin's disease, it can, however, result in undesired suppression in the case of too long treatment with high dose.
 ...
PMID:Levamisole in the treatment of Hodgkin's disease. 31 49

The interaction of levamisole and/or adenosine in vitro on E-rosette forming cells (RFC) of healthy subjects and on low RFC of patients affected with various diseases was investigated. Levamisole did not enhance normal RFC. The drug enhanced low RFC in some patients (responders) but not in others (non-responders). Adenosine inhibited normal and low RFC and this inhibition could be reversed by levamisole. Further, levamisole 150 mg 2 days a week was given to 12 Hodgkin's disease (HD) responders for 2 weeks, then 150 mg 1 day weekly for 2 1/2 months. After one week of treatment RFC increased and the enhancement could be maintained during the whole treatment period. Lastly levamisole in vitro and in vivo diminished serum adenosine deaminase activity in normal subjects and HD patients.
 ...
PMID:Action of levamisole on E-rosette forming cells and serum adenosine deaminase in Hodgkin's disease. 55 10

Cellular responses were studied in patients with Hodgkin's disease before and after levamisole treatment "in vivo" by measuring delayed skin reactivity to various antigens (PPD, Mumps, Candida and SK-SD), and "in vitro" by evaluating lymphocyte capacity to form spontaneous rosettes and to react to the T-cell mitogen PHA. Levamisole was found to significantly increase both the delayed skin reactivity and the number of T-rosette forming lymphocytes. Patients within two years from irradiation had reduced reactivity to PHA and in them levamisole significantly increased this reactivity. On the other hand, patients who had been irradiated more than two years prior to the study had normal reactivity to PHA which tended to decrease under levamisole treatment. It is concluded that levamisole restores the depressed cellular immunity in patients with Hodgkin's disease and its administration might be indicated in patients, especially in the immediate post-irradiation period.
 ...
PMID:Restoration of cellular immune response by levamisole in patients with Hodgkin's disease. 108 52

Immunocorrection was provided to 94 patients with hemoblastoses. Of these, 50 patients suffered from lymphogranulomatosis and 8 from acute leukemias. Levamisole (decaris, Hungary) and the Soviet drug tactivin were applied as immunocorrectors. The effects of levamisole and tactivin in chronic lymphoid leukemia are combined. They are related to immunologic differentiation of the cells. The patients showed an increase of the count of E-RFC, a decline of the B cell count with superficial immunoglobulins, Em-RFC, changes in the T mu: T gamma cell ratio, and the maintenance of the level of serum immunoglobulins. As a result of the continuous administration of immunocorrectors, there was a rise of the count of B cells with immunoglobulins in the cytoplasm. The continuous use of immunocorrectors favours stabilization of the course of the underlying disease, an increase of the patients' life expectancy. In patients with lymphogranulomatosis, the use of levamisole as part of the multimodality treatment leads to an increase of the count of E-RFC, augmentation of the life expectancy. The treatment with immunocorrectors should be carried out under control of the immunity parameters.
 ...
PMID:[The immunological validation and the potentials and prospects of using immunocorrective agents in treating hemoblastoses]. 179 2

Monocyte chemotaxis and its response to levamisole were studied in patients with Hodgkin's disease. Levamisole caused a significant improvement of the deficient monocyte chemotaxis of the patients. By enhancing monocyte functions including chemotaxis, levamisole may contribute to the improvement of cellular immune reactivity, thus increasing the resistance to infections and prolonging the periods of remission.
 ...
PMID:Monocyte chemotaxis and effect of levamisole in Hodgkin's disease. 745 21